WHO Classifies Talc as Probably Carcinogenic: 5 Legal Impacts of the IARC Group 2A Ruling

Key Facts About the WHO Talc Classification

• July 4, 2024: IARC published Monograph Volume 136, upgrading talc to Group 2A ("probably carcinogenic to humans")
• 29 international experts reviewed evidence from human studies, animal research, and mechanistic data
• The classification applies to all forms of talc, including talc without detectable asbestos fibers
• Group 2A is the second-highest cancer certainty level, behind only Group 1 ("carcinogenic to humans")
• Talc was previously classified as Group 2B ("possibly carcinogenic") — a lower certainty level
• Other Group 2A substances include glyphosate (Roundup) and red meat
• Asbestos itself remains Group 1 — the highest classification — alongside tobacco smoke and benzene
• FDA testing found asbestos in 15% of cosmetic talc products tested between 2018 and 2022
• Total talc lawsuits filed exceed 90,000 with 67,115 pending in MDL 2738
• Johnson & Johnson's three bankruptcy attempts to limit talc liability were all rejected by federal courts
• The largest single-plaintiff talc verdict: $1.5 billion (Craft v. J&J, Baltimore, December 2025)
• Research identified 166 mesothelioma patients with cosmetic talc exposure, 73.5% with no other known asbestos source

What Does the IARC Group 2A Classification Actually Mean for Talc?

The International Agency for Research on Cancer operates within the World Health Organization and evaluates substances for their potential to cause cancer in humans. IARC uses a four-tier classification system, and the July 2024 decision to move talc from Group 2B to Group 2A represents a significant scientific upgrade [1].

Group 2A means the evidence of carcinogenicity in humans is "almost sufficient" — one step below the certainty threshold for Group 1 agents like asbestos, tobacco smoke, and benzene [9]. The working group of 29 experts based the reclassification on three pillars: limited evidence for cancer in humans (specifically ovarian cancer), sufficient evidence for cancer in experimental animals, and strong mechanistic evidence that talc exhibits key characteristics of carcinogens in human cells [1].

"The IARC reclassification is significant because it applies to all forms of talc — not just asbestos-contaminated talc. This means the scientific community is recognizing that talc itself may pose cancer risks independent of asbestos contamination, fundamentally changing the litigation landscape."

— Rod De Llano, Founding Partner, Danziger & De Llano

One critical distinction: the classification applies to all forms of talc, including talc that does not contain asbestos or asbestiform fibers. Previous IARC evaluations had separated "talc containing asbestiform fibers" (Group 1) from "talc not containing asbestiform fibers" (Group 2B). The 2024 monograph supersedes this separation, treating talc as a single substance for classification purposes.

Feature	Group 1 (Asbestos)	Group 2A (Talc, 2024)
Classification	"Carcinogenic to humans"	"Probably carcinogenic to humans"
Human evidence	Sufficient	Limited
Animal evidence	Sufficient	Sufficient
Mechanistic evidence	Strong	Strong
Other examples	Tobacco smoke, benzene	Glyphosate, red meat
Certainty level	Highest	Second-highest

How Has the IARC Ruling Changed Mesothelioma Litigation?

The reclassification arrived at a pivotal moment in talc litigation. With more than 67,115 pending lawsuits in multidistrict litigation (MDL 2738) [10] and total filings approaching 100,000, the IARC upgrade gave plaintiffs' attorneys a powerful new evidentiary tool. Jury verdicts following the reclassification reflect its impact.

In 2025 alone, talc verdicts exceeded $2.5 billion. The largest single-plaintiff verdict in talc litigation history came in December 2025, when a Baltimore jury awarded $1.5 billion in Craft v. Johnson & Johnson — a peritoneal mesothelioma case [11]. Two months earlier, a Los Angeles jury returned a $966 million verdict in Moore v. J&J, also involving mesothelioma.

"Before the IARC upgrade, defense attorneys could characterize talc as merely 'possibly' carcinogenic and argue the science was uncertain. That argument is substantially harder to make now. 'Probably carcinogenic' from the WHO's own cancer research agency carries enormous weight with juries."

— Rod De Llano, Founding Partner, Danziger & De Llano

Major talc mesothelioma verdicts (2023–2025)

Date	Case	Verdict	Cancer Type
December 2025	Craft v. J&J (Baltimore, MD)	$1.5 billion	Peritoneal mesothelioma
December 2025	Minnesota	$65.5 million	Mesothelioma
October 2025	Moore v. J&J (Los Angeles, CA)	$966 million	Mesothelioma
July 2025	Boston, MA	$42 million	Mesothelioma
June 2025	Suffolk County, MA	$8 million	Mesothelioma
June 2023	Lee v. J&J (Portland, OR)	$260 million	Mesothelioma

These verdicts also reflect the failure of Johnson & Johnson's three attempts to use the "Texas Two-Step" bankruptcy strategy to limit its talc liability. Federal courts rejected all three attempts, most recently in March 2025, after which the company announced it would "return to the tort system" rather than appeal. This leaves the full litigation pipeline open for individual jury trials.

What Scientific Evidence Links Cosmetic Talc to Mesothelioma?

A 2023 study published in the Journal of Occupational and Environmental Medicine (PMC9847157) documented 166 individuals diagnosed with mesothelioma following cosmetic talc exposure [2]. Of these, 73.5% had no other known asbestos exposure source — their only documented exposure was through consumer talc products.

The study revealed striking patterns. Among the 166 patients, 124 (74.7%) were women and 42 (25.3%) were men. Average duration of talc product use was 40.8 years, with an average latency period of 52.4 years between first exposure and diagnosis [2]. Peritoneal mesothelioma accounted for 31.3% of cases — more than double the 10–15% rate seen in the general mesothelioma population — suggesting a distinct exposure pathway through the reproductive tract when talc is applied to the perineal area.

"The Moline et al. data tells us something critical: for the majority of these patients, cosmetic talc wasn't a secondary exposure — it was the primary and only exposure. That's 73.5% of cases with no occupational asbestos history. The products themselves were the exposure source."

— Rod De Llano, Founding Partner, Danziger & De Llano

Separate research published in the American Journal of Industrial Medicine estimated that approximately 60% of mesothelioma cases in women without documented occupational asbestos exposure may be attributable to long-term cosmetic talc use. While men account for roughly 80% of all mesothelioma diagnoses due to occupational exposure, women face a distinct risk from consumer products containing asbestos-contaminated talc.

Why Did the FDA Withdraw Its Mandatory Talc Testing Rule?

In December 2024, the FDA proposed a rule under the Modernization of Cosmetics Regulation Act (MoCRA) that would have required mandatory asbestos testing [9] in all talc-containing cosmetic products. Testing would have used polarized light microscopy (PLM) and transmission electron microscopy (TEM) — methods capable of detecting trace asbestos fibers. Any detectable level would have rendered a product adulterated under federal law.

One year later, in December 2025, HHS Secretary Robert F. Kennedy Jr. officially withdrew the proposed rule [12], citing "Make America Healthy Again (MAHA) priorities" and the need to "reconsider best means of addressing the issues." This withdrawal left a significant regulatory gap:

• No mandatory federal testing requirement exists for asbestos in cosmetic talc
• Testing remains entirely voluntary — cosmetic companies self-regulate
• The FDA's statutory obligation under MoCRA to establish testing standards still exists but has no timeline
• The EU has moved in the opposite direction, classifying talc as a carcinogen and planning to ban talc in all cosmetics by 2027

The FDA's own testing data underscores the concern. Between 2018 and 2022, the agency found asbestos in approximately 15% of cosmetic talc products tested [9]. In 2019 specifically, 9 of 52 products tested positive — a 17% contamination rate. The FDA itself acknowledged that "asbestos is found in the same rock types that host talc deposits" and "may be inseparable from talc in the mining process" [9].

What Are the 5 Legal Impacts of the IARC Group 2A Ruling?

The reclassification affects mesothelioma litigation in five concrete ways that are already reshaping case outcomes:

1. Stronger causation arguments

The upgrade from "possibly" to "probably" carcinogenic provides plaintiffs with an authoritative international scientific body's conclusion. This is harder for defense experts to counter than individual studies, because IARC's classification represents a consensus evaluation of the total evidence by 29 independent experts [1].

2. Expanded defendant liability

Because the classification applies to all talc — not just asbestos-contaminated talc — manufacturers can no longer rely solely on the argument that their talc was "asbestos-free." The IARC finding suggests talc itself poses cancer risks, which may expose talc suppliers, cosmetic manufacturers. Retailers to liability regardless of contamination testing results.

3. Higher jury awards

Post-reclassification verdicts demonstrate that juries are responding to the upgraded classification [11]. Total 2025 talc verdicts exceeded $2.5 billion, compared to $320 million in mesothelioma talc verdicts during 2024. The $1.5 billion Craft verdict in Baltimore set a new record for single-plaintiff talc litigation.

4. Defeat of corporate bankruptcy strategies

Johnson & Johnson's three failed bankruptcy attempts have left the door open for individual jury trials where the IARC classification can be presented as evidence. The company's decision not to appeal the March 2025 rejection means the full 67,115 pending cases will proceed through the traditional tort system.

5. Regulatory evidence gap benefits plaintiffs

The withdrawal of the FDA's mandatory testing rule, combined with the IARC upgrade, creates a powerful narrative for plaintiffs: the world's leading cancer research authority says talc is probably carcinogenic, yet the United States has no mandatory testing requirement. Juries and judges are likely to view this gap as evidence that the industry has prioritized cost over consumer safety.

Who Can File a Talc Mesothelioma Claim?

If you or a loved one has been diagnosed with mesothelioma and used cosmetic talc products — including baby powder, body powder, or other talc-containing personal care products — you may have grounds for legal action. The Moline et al. 2023 study documented that the majority of cosmetic talc mesothelioma patients had no other occupational asbestos exposure, demonstrating that consumer product exposure alone can be sufficient to cause the disease.

Multiple compensation pathways exist. Asbestos trust funds hold more than $30 billion specifically for victims of asbestos exposure, and claims can be filed simultaneously with civil lawsuits without one reducing the other. The 60+ active bankruptcy trusts include funds established by talc-related defendants.

"Every talc mesothelioma case we evaluate involves reconstructing decades of product use. The IARC classification gives us a scientific foundation that did not exist three years ago. When the WHO says talc is probably carcinogenic, that finding stands alongside the patient's individual exposure history to build the strongest possible case."

— Rod De Llano, Founding Partner, Danziger & De Llano

Key eligibility factors include:

• Diagnosis: Confirmed mesothelioma (pleural, peritoneal, or pericardial)
• Exposure history: Documented use of talc-containing products
• Statute of limitations: Varies by state — filing deadlines are measured from date of diagnosis, not date of exposure
• No requirement for occupational exposure: Consumer product use alone can support a claim

For a free, confidential evaluation of your case, take our case assessment quiz or contact an experienced mesothelioma attorney who understands the evolving talc litigation landscape.

Frequently Asked Questions

What does the WHO IARC Group 2A classification of talc mean?

The WHO International Agency for Research on Cancer reclassified talc from Group 2B ("possibly carcinogenic") to Group 2A ("probably carcinogenic to humans") in July 2024. Group 2A is the second-highest level of cancer certainty, meaning the evidence of carcinogenicity in humans is "almost sufficient." A working group of 29 international experts based the decision on limited evidence in humans, sufficient evidence in animals. Strong mechanistic evidence that talc exhibits key characteristics of carcinogens. This classification applies to all forms of talc, including talc not containing asbestos.

How does the IARC talc ruling affect mesothelioma lawsuits?

The reclassification strengthens plaintiffs' arguments by providing an authoritative international scientific body's conclusion that talc itself is probably carcinogenic. Before July 2024, talc was classified as Group 2B ("possibly carcinogenic"), which defense attorneys could more easily minimize. The upgrade to Group 2A aligns talc with substances like glyphosate, which generated billions in litigation settlements. Jury verdicts after the reclassification have exceeded $2.5 billion in 2025 alone, including a record $1.5 billion single-plaintiff verdict in Baltimore.

What are the largest talc mesothelioma verdicts?

The largest single-plaintiff talc verdict is $1.5 billion, awarded in Craft v. Johnson & Johnson in Baltimore in December 2025 for peritoneal mesothelioma. Other major verdicts include $966 million in Moore v. J&J (Los Angeles, October 2025), $260 million in Lee v. J&J (Portland, June 2023), and the largest aggregate verdict of $4.69 billion for 22 plaintiffs (St. Louis, 2018). Total talc verdicts in 2025 exceeded $2.5 billion.

Is there still asbestos in talc products sold today?

There is as of 2026 no mandatory federal testing requirement for asbestos in cosmetic talc products. FDA testing between 2018 and 2022 found asbestos contamination in approximately 15% of cosmetic talc products tested. Johnson & Johnson ceased selling talc-based baby powder globally in 2023, but other talc-containing products remain on the market. The EU has classified talc as a carcinogen and plans to ban it in all cosmetics by 2027.

Can I file a talc mesothelioma lawsuit if I used cosmetic talc products?

Yes. If you or a loved one has been diagnosed with mesothelioma and has a history of using cosmetic talc products, you may be eligible to file a lawsuit. Research documented 166 individuals with mesothelioma following cosmetic talc exposure, with 73.5% having no other known asbestos source. Multiple compensation pathways exist, including civil lawsuits and asbestos trust fund claims.

What is the difference between talc and asbestos?

Talc and asbestos are both naturally occurring minerals that frequently form in the same geological environments. The IARC Group 2A classification applies to all forms of talc, including talc without detectable asbestos. Tremolite asbestos is the most common type found in talc deposits and is particularly dangerous because its needle-like fibers penetrate deep into lung tissue. The FDA acknowledged that asbestos "may be inseparable from talc in the mining process."

How many talc lawsuits are pending in the United States?

As of March 2026, 67,115 talcum powder lawsuits are pending in multidistrict litigation (MDL 2738) in the District of New Jersey. Total talc lawsuits filed exceed 90,000. The MDL resumed full activity in April 2025 after Johnson & Johnson's third bankruptcy attempt was rejected and the company announced it would not appeal.

What Sources Were Used in This Article?

Regulatory and Scientific Sources

1. IARC Monographs Volume 136: Talc and Acrylonitrile. International Agency for Research on Cancer, World Health Organization. July 4, 2024.
2. Moline JM, et al. "Exposure to cosmetic talc and mesothelioma." Journal of Occupational and Environmental Medicine. 2023. PMC9847157.
3. Moline JM, et al. "Malignant mesothelioma following repeated exposures to cosmetic talc." Journal of Occupational and Environmental Medicine. 2020. PMC7317550.
4. FDA. "Cosmetic Talc Safety." U.S. Food and Drug Administration.
5. FDA Proposed Rule: Asbestos Testing in Talc-Containing Cosmetics. December 2024. Withdrawn December 2025.
6. EPA. "Actions to Protect the Public from Exposure to Asbestos." U.S. Environmental Protection Agency.
7. EPA. "TSCA Risk Evaluation for Asbestos." U.S. Environmental Protection Agency.
8. OSHA. "Asbestos Standards." Occupational Safety and Health Administration.
9. ATSDR. "Asbestos Health Effects." Agency for Toxic Substances and Disease Registry.
10. NCI. "Malignant Mesothelioma Treatment." National Cancer Institute.
11. NCI SEER Program. "Mesothelioma Incidence and Mortality Data."
12. Wiley Rein LLP. "FDA Withdraws Standardized Asbestos Testing Proposal." December 2025.

Court Records

• MDL 2738: In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation (D.N.J.)
• Craft v. J&J: Circuit Court for Baltimore City, MD (December 2025)
• Moore v. J&J: Los Angeles Superior Court, CA (October 2025)
• Lee v. J&J: Portland, OR (June 2023)
• Red River Talc LLC Bankruptcy: Case No. 24-90505 (S.D. Tex.), rejected March 2025